In spite of these observations, several publications deal with the neurotoxic effect of fractalkine in many models of chronic neurodegenerative disorders, e.g. Alzheimer’s disease and Parkinson’s disease (Liu et al. 2010; Shan et al. 2011). This evidence concerns the gene CX3CL1 and early-onset autosomal dominant Alzheimer disease.